Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

The Lancet Oncology

Volumn 18, Issue 10, 2017, Pages 1386-1396

  van Zandwijk, Nico ^a,g   Pavlakis, Nick ^b,g   Kao, Steven C ^a,c,g   Linton, Anthony ^f   Boyer, Michael J ^c,g   Clarke, Stephen ^b,g   Huynh, Yennie ^a,g   Chrzanowska, Agata ^a,g   Fulham, Michael J ^d,g   Bailey, Dale L ^e,h   Cooper, Wendy A ^d,g,i   Kritharides, Leonard ^f,g   Ridley, Lloyd ^f   Pattison, Scott T ^j   MacDiarmid, Jennifer ^j   Brahmbhatt, Himanshu ^j   Reid, Glen ^a,g  

^a Asbestos Diseases Research Institute   (Australia)

^b CANCER INSTITUTE NSW   (Australia)

^c Chris o'Brien Lifehouse   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f Department of Microbiology and Infectious Diseases   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY OF WESTERN SYDNEY   (Australia)

^j Engeneic Ltd   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; RNA DERIVATIVE; TARGOMIRS; UNCLASSIFIED DRUG; MICRORNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUSTRALIA; BONE MARROW; CANCER CHEMOTHERAPY; CANCER GROWTH; CARDIOMYOPATHY; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; ELECTROCARDIOGRAPHY; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; INFUSION RELATED REACTION; INTESTINE PERFORATION; KIDNEY FUNCTION; LIFE EXPECTANCY; LIVER FUNCTION; LYMPHOCYTOPENIA; MALE; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAKOTSUBO CARDIOMYOPATHY; TUMOR GROWTH; AGED; CANCER CENTER; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEEDLE BIOPSY; PATHOLOGY; PATIENT SAFETY; PATIENT SELECTION; PLEURAL NEOPLASMS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AUSTRALIA; BIOPSY, NEEDLE; CANCER CARE FACILITIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT SAFETY; PATIENT SELECTION; PLEURAL NEOPLASMS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85028676559     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30621-6     Document Type: Article

References (38)

1. Schunselaar, LM, Quispel-Janssen, JM, Neefjes, JJ, Baas, P, A catalogue of treatment and technologies for malignant pleural mesothelioma. Expert Rev Anticancer Ther 16 (2016), 455–463.
2. Zalcman, G, Mazieres, J, Margery, J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387 (2016), 1405–1414.
3. Bartel, DP, MicroRNAs: target recognition and regulatory functions. Cell 136 (2009), 215–233.
4. Ameres, SL, Zamore, PD, Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 14 (2013), 475–488.
5. Friedman, RC, Farh, KK, Burge, CB, Bartel, DP, Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19 (2009), 92–105.
6. Calin, GA, Dumitru, CD, Shimizu, M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15 (2002), 524–529.
7. Bandi, N, Zbinden, S, Gugger, M, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69 (2009), 5553–5559.
8. Bonci, D, Coppola, V, Musumeci, M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14 (2008), 1271–1277.
9. Reid, G, Pel, ME, Kirschner, MB, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol 24 (2013), 3128–3135.
10. MacDiarmid, JA, Brahmbhatt, H, Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. Curr Opin Biotechnol 22 (2011), 909–916.
11. Agarwal, V, Lind, MJ, Cawkwell, L, Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treat Rev 37 (2011), 533–542.
12. Dazzi, H, Hasleton, PS, Thatcher, N, Wilkes, S, Swindell, R, Chatterjee, AK, Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 61 (1990), 924–926.
13. MacDiarmid, JA, Mugridge, NB, Weiss, JC, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11 (2007), 431–445.
14. Byrne, MJ, Nowak, AK, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15 (2004), 257–260.
15. Solomon, BJ, Desai, J, Rosenthal, M, et al. A first-time-in-human phase I clinical trial of bispecific antibody-targeted, paclitaxel-packaged bacterial minicells. PLoS One, 10, 2015, e0144559.
16. Postel-Vinay, S, Collette, L, Paoletti, X, et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents—dose-limiting toxicity and toxicity assessment recommendation group for early trials of targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. Eur J Cancer 50 (2014), 2040–2049.
17. Cedres, S, Ponce-Aix, S, Zugazagoitia, J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One, 10, 2015, e0121071.
18. Stylianopoulos, T, Jain, RK, Design considerations for nanotherapeutics in oncology. Nanomedicine 11 (2015), 1893–1907.
19. MacDiarmid, JA, Amaro-Mugridge, NB, Madrid-Weiss, J, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 27 (2009), 643–651.
20. MacDiarmid, JA, Langova, V, Bailey, D, et al. Targeted doxorubicin delivery to brain tumors via minicells: proof of principle using dogs with spontaneously occurring tumors as a model. PLoS One, 11, 2016, e0151832.
21. Kirschner, MB, Kao, SC, Edelman, JJ, et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One, 6, 2011, e24145.
22. Whittle, JR, Lickliter, JD, Gan, HK, et al. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J Clin Neurosci 22 (2015), 1889–1894.
23. Brotfain, E, Schwartz, A, Boniel, A, et al. Clinical outcome of critically ill patients with thrombocytopenia and hypophosphatemia in the early stage of sepsis. Anaesthesiol Intensive Ther 48 (2016), 294–299.
24. Schwartz, A, Gurman, G, Cohen, G, et al. Association between hypophosphatemia and cardiac arrhythmias in the early stages of sepsis. Eur J Intern Med, 13, 2002, 434.
25. Porrello, ER, Mahmoud, AI, Simpson, E, et al. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc Natl Acad Sci USA 110 (2013), 187–192.
26. Smeding, L, Plotz, FB, Groeneveld, AB, Kneyber, MC, Structural changes of the heart during severe sepsis or septic shock. Shock 37 (2012), 449–456.
27. Dowdy, SF, Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 35 (2017), 222–229.
28. Beg, MS, Brenner, AJ, Sachdev, J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 35 (2017), 180–188.
29. Meng, Z, Lu, M, RNA Interference-induced innate immunity, off-target effect, or immune adjuvant?. Front Immunol, 8, 2017, 331.
30. Boutin, C, Viallat, JR, Van Zandwijk, N, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 67 (1991), 2033–2037.
31. Sterman, DH, Alley, E, Stevenson, JP, et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNalpha combined with chemotherapy. Clin Cancer Res 22 (2016), 3791–3800.
32. Kao, SC, Cheng, YY, Williams, M, et al. Tumour suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J Thorac Oncol, 2017 published online June 16. DOI:10.1016/j.jtho.2017.05.024.
33. Wang, X, Li, J, Dong, K, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal 27 (2015), 443–452.
34. Thapa, B, Watkins, DN, John, T, Immunotherapy for malignant mesothelioma: reality check. Expert Rev Anticancer Ther 16 (2016), 1167–1176.
35. Buikhuisen, WA, Hiddinga, BI, Baas, P, van Meerbeeck, JP, Second line therapy in malignant pleural mesothelioma: a systematic review. Lung Cancer 89 (2015), 223–231.
36. Raphael, J, Le Teuff, G, Hollebecque, A, et al. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution. Lung Cancer 85 (2014), 251–257.
37. Kao, SC, Fulham, M, Wong, K, et al. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. Am J Respir Crit Care Med 191 (2015), 1467–1469.
38. Szlosarek, PW, Steele, JP, Nolan, L, et al. Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial. JAMA Oncol 3 (2017), 58–66.